Moran Sean F. 4

Accession 0000950170-24-075075

CIK 0001595097other

View on SEC.gov Company Profile

Filed

Jun 17, 8:00 PM ET

Accepted

Jun 18, 5:59 PM ET

Size

26.0 KB

Accession

0000950170-24-075075

Insider Transaction Report

Form 4

Period: 2024-06-14

Corbus Pharmaceuticals Holdings, Inc.CRBP

Moran Sean F.

Chief Financial Officer

Transactions

Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-18$30.00/sh+1,958$58,740→ 50,563 total
Sale
Common Stock, par value $0.0001 per share
2024-06-18$42.12/sh−1,958$82,479→ 48,605 total
Exercise/Conversion
Options to purchase common stock
2024-06-18−1,958→ 0 total
Exercise: $30.00Exp: 2024-10-22→ Common Stock (1,958 underlying)
Sale
Common Stock, par value $0.0001 per share
2024-06-14$49.87/sh−7,788$388,417→ 48,605 total
Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-17$14.10/sh+6,730$94,893→ 55,335 total
Exercise/Conversion
Options to purchase common stock
2024-06-14−1,567→ 1,958 total
Exercise: $30.00Exp: 2024-10-22→ Common Stock (1,567 underlying)
Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-14$4.26/sh+7,788$33,177→ 56,393 total
Sale
Common Stock, par value $0.0001 per share
2024-06-17$46.77/sh−6,730$314,789→ 48,605 total
Sale
Common Stock, par value $0.0001 per share
2024-06-14$49.87/sh−1,567$78,152→ 48,605 total
Exercise/Conversion
Common Stock, par value $0.0001 per share
2024-06-14$30.00/sh+1,567$47,010→ 50,172 total
Exercise/Conversion
Options to purchase common stock
2024-06-14−7,788→ 23,367 total
Exercise: $4.26From: 2024-02-13Exp: 2033-02-13→ Common Stock (7,788 underlying)
Exercise/Conversion
Options to purchase common stock
2024-06-17−6,730→ 11,217 total
Exercise: $14.10From: 2023-02-01Exp: 2032-02-01→ Common Stock (6,730 underlying)

Footnotes (8)

[F1]This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.
[F2]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.
[F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.26 to $52.525 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
[F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.88 to $49.47 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
[F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.10 to $43.59 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
[F6]The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.
[F7]The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.
[F8]The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 1, 2023, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2023.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

Corbus Pharmaceuticals Holdings, Inc.

CIK 0001595097

→

Entity typeother

Related Parties

filerCIK 0001451495

Filing Metadata

Form type: 4
Filed: Jun 17, 8:00 PM ET
Accepted: Jun 18, 5:59 PM ET
Size: 26.0 KB

View on SEC.gov